GSK Acquires Full Rights for COVID and Flu Vaccines from CureVac in New Restructured Deal

CureVac N.V. has announced a strategic restructuring to focus on high-value mRNA projects in oncology and other areas of unmet medical need. This restructuring includes reducing its workforce by approximately 30% to streamline operations and enhance its focus on technology innovation, research, and development. The move follows a new licensing agreement with GSK, valued at up to €1.45 billion, including €400 million upfront and up to €1.05 billion in milestone payments and royalties. This agreement is expected to extend CureVac's cash runway into 2028, with operational expenses anticipated to decrease by more than 30% from 2025 onwards.

Under the new agreement, GSK will assume full control over the development and manufacturing of several mRNA-based vaccine candidates, including those for influenza and COVID-19. The collaboration, which began in 2020 during the COVID-19 pandemic, aimed to develop vaccines using mRNA technology. GSK's acquisition of these rights will enable both companies to prioritize their respective mRNA development activities. The deal is pending antitrust and regulatory approvals and customary closing conditions. The restructuring allows CureVac to concentrate on its core strengths while benefiting from the financial terms of the agreement.